Bracket buys ePRO provider Arrowhead

As patient reported outcomes become more common in clinical trials, eClinical software provider Bracket has bought Arrowhead Electronic Healthcare. Austin-based Arrowhead boosts the buyer's electronic patient reported outcomes (ePRO) offerings as the company moves to tackle the growing market for such technology in clinical research. 

This is the first acquisition for Bracket since the firm, a unit of Medco Health's ($MHS) contract research outfit United BioSource, was publicly unveiled in June. Bracket plans to add 25 employees from Arrowhead as well as the acquired company's operation in Austin to its global organization of some 450 people, Adam Butler, vice president of client services at Bracket, told FierceBiotech IT. Financial terms of the deal weren't disclosed.

Arrowhead, which was founded in 1999, brings Bracket a set of ePRO products that enable a patient in a clinical trial to report his or her status via smartphones, tablet computers, the Web and text messaging. Its technology builds on Bracket's previous clinical trials software offerings--some of which include an interactive voice response system (IVRS), endpoint reliability technology and computerized cognitive testing.

Bracket has been in the works since last year and was created through the combination of UnitedBioSource's clinical technologies and clinical services businesses to capitalize on growing demand for the groups' technologies from drug developers and CROs, Butler said. The new group is expected to weigh further buyouts as part of its strategy to grow through both internal investments in technology development and acquisitions.

"We're going to continue to evaluate companies and technologies that we think would make the way we are collecting and managing data in clinical trials work better," Butler said in an interview.

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.